Risk of sales discontinuation due to adverse reactions
First written in FY2017. 5 of 6 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2026: 6 of 21 companies on the "Worse" side.
41 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「If an unforeseen adverse reaction emerges and the company is forced to recall a product or discontinue its sales, this may have a material impact on the Group's operating results and financial position.」
The risk of product recalls or sales discontinuation due to unforeseen post-marketing adverse reactions continues to be reported. - FY2022RestatedAnnual report
「If an unforeseen adverse reaction emerges and the company is forced to recall a product or discontinue its sales, this may have a material impact on the Group's operating results and financial position.」
The company continues to report the risk of product recalls or sales discontinuation due to unforeseen post-marketing adverse reactions. - FY2021RestatedAnnual report
「If an unforeseen adverse reaction emerges and the company is forced to recall a product or discontinue its sales, this may have a material impact on the Group's operating results and financial position.」
The company continues to identify as a risk the possibility that unforeseen post-marketing adverse reactions may lead to product recalls or sales discontinuation. - FY2019RestatedAnnual report
「Post-marketing surveillance is conducted to supplement clinical trials after a product is launched. If a new adverse reaction emerges, sales may be discontinued.」
The company continues to report the risk of sales discontinuation if a new adverse reaction emerges during post-marketing surveillance. - FY2018RestatedAnnual report
「If a new adverse reaction emerges, sales may be discontinued.」
The company continues to report the risk of sales discontinuation if a new adverse reaction emerges during post-marketing surveillance. - FY2017First statedAnnual report
「Post-marketing surveillance is conducted to supplement clinical trials after a product is launched. If a new adverse reaction emerges, sales may be discontinued.」
The company identifies as a risk the possibility that sales may be discontinued if a new adverse reaction emerges during post-marketing surveillance.